Caristo Diagnostics
About Caristo Diagnostics
Caristo Diagnostics is a global leader in AI-powered cardiac and vascular disease diagnostics and risk prediction, spun out from the University of Oxford. The company’s flagship technology, CaRi-Heart®, utilizes advanced AI algorithms to analyze routine cardiac CT angiography (CCTA) scans. This innovative approach allows for the visualization and quantification of perivascular fat inflammation, a previously invisible yet critical biomarker for coronary artery disease (CAD) and a strong predictor of future cardiac events, often years before symptoms manifest.
For physicians, CaRi-Heart provides a comprehensive report that includes the patient-specific Fat Attenuation Index (FAI), a patented biomarker for coronary inflammation, and an individualized CaRi-Heart Risk score, which assesses the absolute 8-year risk of a fatal heart attack by integrating inflammation status with standard clinical risk factors and plaque presence. The technology aims to transform cardiac care from a reactive model to a proactive one, enabling earlier detection, personalized prevention strategies, and refined treatment decisions. Caristo also offers CaRi-Plaque™ technology for quantitative characterization of coronary plaque and stenosis. The CaRi-Heart technology is CE Mark certified for use in the UK, EU, and Australia, and the company is actively pursuing FDA clearance and CPT codes for broader adoption in the U.S.
Focus Areas
Business Intelligence
| Key Investors | Oxford Science Enterprises, BGF, Longwall Venture Partners, Oxford Investment Consultants LLP, Oxford University, Oxford Technology Investment Fund, HealthTech Arkansas Programs, HeartX Accelerator, MedAxiom, Oxford Technology Management |
| Partnerships | MedAxiom, NHS AI Stage 3 Award, Biograph (US study), Cromwell Hospital, Hooke London, myGP Clinic, Groupe Prive Hospitalier Ambroise Paré Hartmann, major global pharmaceutical and biotech companies, Aetna, Cigna, Humana, UnitedHealthcare (coverage), Centers for Medicare & Medicaid Services (CMS) |
| Technology | CaRi-Heart® technology, CaRi-Plaque™ technology, AI-assisted diagnostics, cloud-based Software as a Service (SaaS) medical device, advanced AI algorithms applied to routine cardiac CT scans (CCTA), Fat Attenuation Index (FAI-Score™) |
| FDA Clearances | 1 cleared products (estimated) |
What Physicians Need to Know
For physicians, Caristo Diagnostics offers a paradigm shift in cardiovascular care by enabling earlier and more precise risk stratification. The CaRi-Heartu00ae and CaRi-Plaqueu2122 analyses provide critical insights into coronary inflammation and plaque characteristics that are not visible with standard CCTA interpretation alone. This allows for proactive intervention, personalized treatment strategies (including lifestyle modifications and targeted medications), and improved patient outcomes, particularly for those with non-obstructive CAD who are often misclassified as low risk. The rapid turnaround of reports (typically within 48 hours) facilitates timely clinical decision-making.
Caristo's CaRi-Heartu00ae platform is a cloud-based Software as a Service (SaaS) medical device designed for seamless integration into existing clinical workflows. It accepts de-identified CCTA scans from most scanner models or PACS systems via secure and anonymized data transfer. The analysis results are delivered to healthcare professionals as intuitive, actionable reports in either DICOM-conformant files or PDF format. For users of CaRi-Plaqueu2122, there is a seamless adoption pathway for CaRi-Heartu00ae once it receives full FDA clearance in the US.
What the Web Says
Caristo Diagnostics is an Oxford, UK-based company specializing in AI-powered cardiovascular imaging and diagnostics. Their flagship product, CaRi-Heart, utilizes advanced AI algorithms on routine cardiac CT scans to visualize and quantify coronary inflammation, a key indicator of heart attack risk. The company has received positive attention for its innovative approach to preventative cardiac care, with studies suggesting its technology could significantly reduce cardiac deaths and costs.
Overall: PositiveStrengths
- AI-powered technology for early heart attack prediction (up to 10 years in advance)
- Identifies coronary inflammation, a previously invisible root cause of heart disease
- Cloud-based software, agnostic to the type of scanner
- Clinically validated and supported by studies published in leading medical journals
- Potential to reduce cardiac deaths and healthcare costs
- FDA 510(k) clearance for CaRi-Plaque for coronary plaque detection
Limitations
- CaRi-Heart is currently for investigational use only in the United States, though CaRi-Plaque has FDA clearance
- Limited information on employer reviews from major platforms like Glassdoor or Indeed
- Some Reddit discussions express concerns about the cost and potential for insurance companies to use such technology to deny claims or increase premiums
- Early evidence about clinical utility of CaRi-Heart Risk is underdeveloped and has limitations in terms of risk of bias and applicability to UK clinical practice
- Lack of information on how treatment could change as a result of using CaRi-Heart and whether any changes would improve outcomes for patients
Based on reviews from: Caristo Diagnostics Official Website, Medical Device Network, Indeed.com, PMC (PubMed Central), BioWorld, Newsweek, AuntMinnie, PR Newswire, Reddit, Scam Detector
Last updated: 2026-07-18
Videos
News, demos, and interviews about Caristo Diagnostics.
Videos load interactively. If none appear, search YouTube for Caristo Diagnostics →
Press & Coverage
Frequently Asked Questions
Related Companies
Google DeepMind is a leading artificial intelligence (AI) research laboratory, a subsidiary of Alphabet Inc., dedicated to developing advanced AI systems to benefit humanity. The company focuses on creating general-purpose AI that can learn and solve complex problems, drawing inspiration from neuroscience and machine learning. Their work spans various fields, including healthcare, scientific discovery, and […]
TalkToMedi is a Canadian healthcare AI company that has developed a clinical-grade voice AI platform called MEDI. This platform is designed to automate patient communication and administrative tasks for medical clinics, including family medicine, specialty clinics, allied health, and physiotherapy. MEDI handles high-volume patient calls, automating appointment inquiries, booking, rescheduling, and cancellations based on the […]
Menaela is an AI-first practice management system designed for solo practitioners, small private clinics, and clinic owners. It integrates patient communication, scheduling, CRM, and medical documentation into a single platform, aiming to replace multiple disconnected tools and bots. The system features an AI practice manager that understands natural-language requests, utilizes real clinic data, and performs […]
Avie is operated by AVIE TECNOLOGIA LTDA, headquartered in Santo André, São Paulo, Brazil. Avie provides WhatsApp reception in Brazilian Portuguese, appointment scheduling, rescheduling and cancellations through Google Calendar or Feegow, clinic CRM, follow-up messages and an online booking website. Clinic staff can review conversations and take over when human support is needed. Clinic CRM […]
Saile is a physician-founded healthcare technology company that addresses critical inefficiencies in healthcare staffing and credentialing. Their AI-powered platform acts as a “universal credential passport” for physicians, centralizing and managing all medical licenses, certifications, and CME credits in one secure, portable vault. This system aims to significantly reduce the administrative burden and delays associated with […]
Data Capture Experts (DCE) is an Australian-based healthcare AI company that is at the forefront of digital health transformation. They specialize in developing and implementing digital health platforms that integrate data, technology, and human-centered design to create intuitive and connected healthcare systems. Their flagship platform, DC2Vue, is designed to go beyond traditional Electronic Medical Records […]